Kristin Ludwig named vice president of global corporate communications at EQRx

New drugs don’t appear out of thin air

As a physician-scientist who has navigated drug development from lab bench to bedside to executive boardroom, I want to touch upon a subject that is near and dear to my heart: the state of American science—a linchpin of our healthcare system and national competitiveness.

March 14, 2025

Vol.51 No.10

By William Pao

In Brief

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.

October 25, 2024

Vol.50 No.40

In Brief

Alex Morozov named chief medical officer at Pi Health

Alex Morozov was named the first chief medical officer of Pi Health, an oncology clinical trial and research technology company.

August 09, 2024

Vol.50 No.32

Drugs & Targets

Pierre Fabre Laboratories acquires Vertical Bio

Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies.

September 15, 2023

Vol.49 No.34

Drugs & Targets

Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines

Portage Biotech Inc., NCI, and Stimunity entered a Cooperative Research and Development Agreement, under which they will collaborate with NCI’s Center for Cancer Research to advance preclinical and potential clinical development of STING agonists and anti-Receptor for Advanced Glycation End products (RAGE) agents to enhance the efficacy of cancer vaccines developed in the NCI CCR Vaccine Branch.

April 29, 2022

Vol.48 No.17